Home Compare BSX vs NBIX
Stock Comparison · Structural lead, mixed market

Boston Scientific vs Neurocrine Biosciences: Which Stock Looks Stronger in 2026?

Neurocrine Biosciences holds the cleaner structural position, with growth as the main driver and stability adding further support. The market setup broadly confirms the structural lead — Neurocrine Biosciences holds the more constructive position. That puts structure and market broadly in agreement — Neurocrine Biosciences's lead looks more confirmed than conflicted.

The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the Russell 1000 universe, making them directly comparable.

Updated 2026-08-16

Growth still does most of the heavy lifting in this comparison. Neurocrine Biosciences, Inc. leads by 12 points on the overall comparison score.

Trajectory Similarity
0.75
Similar
Peer-set rank: #1
within Boston Scientific Corporation's functional peer set

This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.

This level of similarity signals a strong structural match, even though some dimensions still separate the two companies.

The clearest structural overlap shows up in recent revenue growth and margin consistency.

Similarity drivers
recent revenue growthmargin consistency
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
BSX
Boston Scientific Corporation
50
Peer-Score
Signal qualitylow
Peer basis: Russell 1000
vs
NBIX
Neurocrine Biosciences, Inc.
62
Peer-Score
Signal qualitylow
Peer basis: Russell 1000

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: BSX vs NBIX Profitability 33 34 Stability 59 75 Valuation 86 78 Growth 14 66 BSX NBIX
Gap Ranking
#1 Growth +52
#2 Stability +16
#3 Valuation +8
#4 Profitability +1
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for BSX and NBIX Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer BSXNBIX Relative valuation Structural strength

The setup remains mixed because the stronger profile and the more supportive price setup do not sit on the same side.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Entry today — historical context

Where BSX and NBIX each sit in their own 5-year price and valuation history.

BASED ON 5-YEAR HISTORY BSX Neutral · below norm 0th 50th 100th 50 pct gap NBIX Elevated · below norm 0th 50th 100th 43rd 94th
Today BSX sits in the lower-middle of its own 5-year history (43rd percentile), while NBIX sits higher in its own history (94th). Within each stock's own 5-year context, BSX is at a historically more favourable entry position than NBIX. This reflects entry timing, not which company is structurally stronger — peer-relative analysis is a separate question addressed above.

Describes historical entry positioning only. Descriptive — not investment advice.

Relative Position vs Comparable Companies
Growth
On growth, Neurocrine Biosciences, Inc. ranks near the top of the group; Boston Scientific Corporation sits in the weaker half.
Stability
On stability, the same pattern holds: both rank well, but Neurocrine Biosciences, Inc. still sits higher.
Growth — Dominant Gap
BSX
14
NBIX
66
Gap+52in favour of NBIX

Revenue growth reinforces the category-level growth lead.

What else supports the lead

Stability adds another layer of support rather than leaving the result tied to growth alone.

What this means for the comparison

Growth is the clearest driver, and stability also supports Neurocrine Biosciences, Inc.'s broader structural position.

Explore full peer positioning in AssetNext

Break down the BSX vs NBIX comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-driven comparisons

Explore how BSX and NBIX each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.